News
Video
Author(s):
Scott Plotkin, MD, reviews data from a phase II study on brigatinib, a multi tyrosine kinase inhibitor, across various tumor types in patients with NF2-related schwannomatosis.
Tivozanib Monotherapy Bests Lower-Dose Tivozanib Plus Nivolumab in Metastatic RCC
Frontline BMS-986012 Plus Nivolumab/Chemotherapy Shows Promise in ES-SCLC
Belzutifan Maintains PFS, ORR Benefits in Previously Treated Advanced Clear Cell RCC
Dr Wilky on a Study of Botensilimab Plus Balstilimab in Refractory Metastatic Sarcoma
2 Commerce Drive
Cranbury, NJ 08512